This document describes the regulatory framework for biosimilar medicines in the European Union, including their definition, development and approval procedures, and the safety of biosimilar medicines.
This document, jointly developed by the European Medicines Agency (EMA) and the European Commission, provides healthcare professionals with scientific and regulatory information on biosimilar medicines. It explains how biosimilars are developed, authorized, and monitored for safety in the EU. The guide emphasizes that biosimilars are highly similar to already-approved reference biologics and are subject to the same quality, safety, and efficacy standards. It also addresses safety monitoring, extrapolation of indications, and the role of national authorities in interchangeability decisions.
The document includes sections on the definition of biosimilars, regulatory procedures, immunogenicity, safety monitoring, traceability, and patient communication. It highlights that biosimilars have been safely used in the EU since 2006 and that their approval relies on comprehensive comparability studies and scientific evidence. This manual is written in Italian.
Biosimilar medicines are highly similar to an already-approved biologic medicine (the 'reference medicine') in all essential aspects.
Yes, biosimilar medicines authorized by the EMA have the same safety and efficacy as the reference medicines for the authorized indications.
The European Medicines Agency (EMA) and the European Commission jointly regulate biosimilar medicines in the EU.
No, biosimilar medicines are monitored for safety through the same pharmacovigilance system as all other medicines in the EU.